Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Exagen Inc (XGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Exagen's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.350 -0.010    -0.74%
02/05 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 1,207
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.350 - 1.350
Type:  Equity
Market:  United States
Exagen 1.350 -0.010 -0.74%

Exagen Inc Company Profile

 
Get an in-depth profile of Exagen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Providers & Services
SectorHealthcare
Employees

202

Equity Type

ORD

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Contact Information

Address 1261 Liberty Way Suite C
Vista, 92081
United States
Phone 760 560 1501
Fax -

Top Executives

Name Age Since Title
Mark D. Pegram - - Member of Breast Cancer Advisory Board
Raymond R. Tubbs - - Member of Breast Cancer Advisory Board
Lyndsay N. Harris - - Member of Breast Cancer Advisory Board
Michael F. Press - - Member of Breast Cancer Advisory Board
Kenneth J. Bloom 66 - Member of Breast Cancer Advisory Board
William J. Sandborn 61 - Member of Science Advisory Board
Tina S. Nova 70 2019 Executive Chairman of the Board of Directors
Brian Peter Birk 65 2008 Independent Director
Stephen B. Hanauer - - Member of Science Advisory Board
Thomas Williams - - Member of Breast Cancer Advisory Board
David T. Rubin - - Member of Science Advisory Board
Anca Dinu Askanase - 2019 Member of Scientific Advisory Board
Ebetuel Pallares 51 2012 Independent Director
Bruce C. Robertson 61 2019 Independent Director
Harris Perlman - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
Kevin Deane - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
John Aballi 39 2022 CEO, President & Director
Stanley B. Cohen - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
Andrew L. Concoff - 2019 Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
Vasileios Kyttaris - 2019 Member of Scientific Advisory Board
Joel M. Kremer - - Member of Scientific Advisory Board
Paul J. DeMarco - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
Frank Stokes 53 2021 Independent Director
Arthur Weinstein 80 2013 Chairman of Scientific Advisory Board
Ana Hooker 57 2021 Independent Director
Eric M. Ruderman - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
Marina Sirota - 2022 Member of Rheumatoid Arthritis Scientific Advisory Board
Wendy S. Johnson 72 2020 Independent Director
Maureen A. McMahon - 2019 Member of Scientific Advisory Board
Paul Kim 57 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

XGN Comments

Write your thoughts about Exagen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email